Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORDElectronic Journal of Biotechnology.  131:1463-1472.e7. 2018
2018 Advances in resistant hypertension.Journal of Social Behavior and Personality.  6:294. 2018
2018 Early feasibility of hypoglossal nerve upper airway stimulator in patients with cardiac implantable electronic devices and continuous positive airway pressure-intolerant severe obstructive sleep apneaHeart Rhythm.  15:1165-1170. 2018
2018 Case of refractory hypertension controlled after aortic and mitral valve replacement and coronary artery bypass graftingHypertension.  72:3-9. 2018
2018 Cumulative incidence of hypertension by 55 years of age in blacks and whites: The cardia studyJournal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  7. 2018
2018 Fluid retention, aldosterone excess, and treatment of resistant hypertensionLancet Diabetes and Endocrinology.  6:431-433. 2018
2018 Medical versus surgical treatment of primary aldosteronismHypertension.  71:566-568. 2018
2018 Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic SyndromeConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  20. 2018
2018 The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart StudyJournal of Clinical Hypertension.  20:438-446. 2018
2018 Antihypertensive Medications and Falls in the ElderlyJournal of Immunology.  31:281-283. 2018
2018 The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in AdultsJournal of Immunology.  31:133-135. 2018
2018 Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumesHypertension.  72:343-349. 2018
2017 Prevalence and clinical characteristics of refractory hypertensionJournal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  6. 2017
2017 True versus pseudoresistant hypertensionJournal of Hypertension.  35:2367-2368. 2017
2017 Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated with Elevated Urinary Mitochondrial-DNA Copy NumberJournal of Immunology.  30:1112-1119. 2017
2017 Refractory versus resistant hypertension: Novel distinctive phenotypes.Journal of nature and science.  3. 2017
2017 Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoeaJournal of Human Hypertension.  31:561-567. 2017
2017 White-Coat Effect Is Uncommon in Patients with Refractory HypertensionHypertension.  70:645-651. 2017
2017 Resistant Hypertension: An Update of Experimental and Clinical FindingsHypertension.  70:5-9. 2017
2017 Distinctive Risk Factors and Phenotype of Younger Patients with Resistant Hypertension: Age is RelevantHypertension.  69:827-835. 2017
2017 Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart StudyJournal of the American Society of Hypertension.  11:204-212.e5. 2017
2017 National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertensionCureus.  186:29-39. 2017
2017 Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHATElectronic Journal of Biotechnology.  130:439-448.e9. 2017
2017 Assessment of vascular function in low socioeconomic status preschool children: a pilot studyJournal of the American Society of Hypertension.  11:101-109. 2017
2017 Sleep, insomnia, and hypertension: current findings and future directionsJournal of the American Society of Hypertension.  11:122-129. 2017
2017 Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant HypertensionJournal of Immunology.  30:103-109. 2017
2017 11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertensionJournal of Immunology.  30:518-523. 2017
2017 Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults secondary analysis of a randomized clinical trialJAMA Internal Medicine.  177:67-76. 2017
2017 Effects of spironolactone and renal denervation treatment on blood pressure and its variability-different aspects of hypertension treatmentJournal of Immunology.  30:12-15. 2017
2017 Refractory versus resistant hypertensionJournal of Commodity Science and Technology.  26:14-19. 2017
2017 Screening for endocrine hypertension: An endocrine society scientific statementRecent Progress in Hormone Research.  38:103-122. 2017
2017 Sleep disorders and hypertension riskJournal of Human Hypertension.  31:371-372. 2017
2017 Update From the Editors to Our Readers.Journal of Immunology.  30:1-2. 2017
2016 Sympathetic Activity, Hypertension, and the Importance of a Good Night's SleepHypertension.  68:1338-1339. 2016
2016 Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertensionRespirology.  21:1486-1492. 2016
2016 BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?Solid-State and Integrated Circuit Technology.  18. 2016
2016 Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients with Resistant HypertensionHypertension.  68:995-1003. 2016
2016 Do we need a new definition of hypertension after SPRINTJournal of Immunology.  29:1127-1129. 2016
2016 Renal Nerve Denervation, Adherence, and Management of Resistant HypertensionMaterials Today: Proceedings.  134:858-860. 2016
2016 OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN.Journal of Hypertension.  34 Suppl 1:e244. 2016
2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.Journal of Hypertension.  34 Suppl 1:e393. 2016
2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.Journal of Hypertension.  34 Suppl 1 - ISH 2016 Abstract Book:e393. 2016
2016 Refractory and resistant hypertension: Antihypertensive treatment failure versus treatment resistanceKorean Circulation Journal.  46:593-600. 2016
2016 SY 14-3 PRIMARY ALDOSTERONISM IN RESISTANT HYPERTENSION.Journal of Hypertension.  34 Suppl 1:e369. 2016
2016 SY 14-3 PRIMARY ALDOSTERONISM IN RESISTANT HYPERTENSION.Journal of Hypertension.  34 Suppl 1 - ISH 2016 Abstract Book:e369. 2016
2016 Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertensionJournal of Hypertension.  34:1701-1703. 2016
2016 The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationaleJournal of receptor research.  50:238-244. 2016
2016 A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertensionJournal of the American Society of Hypertension.  10:510-516.e1. 2016
2016 Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurementJournal of the American Society of Hypertension.  10:493-499. 2016
2016 Refractory hypertension: A novel phenotype of antihypertensive treatment failureHypertension.  67:1085-1092. 2016
2016 Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment FailureMeasurement Techniques.  32:603-606. 2016
2016 Urinary sodiumexcretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone statusJournal of Hypertension.  34:1005-1010. 2016
2016 Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  18. 2016
2016 Introduction to the American Heart Association's hypertension strategically focused research networkHypertension.  67:674-680. 2016
2016 Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal AncestryJournal of Surgical Orthopaedic Advances.  9:26-36. 2016
2016 Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step beyond Observed RiskHypertension.  67:275-277. 2016
2016 A message from the new editorial team at the American Journal of HypertensionJournal of Immunology.  29:1. 2016
2016 Effects of 6-month supplementation with β-hydroxy-β-methylbutyrate, glutamine and arginine on vascular endothelial function of older adultsEuropean Journal of Clinical Nutrition.  70:269-273. 2016
2016 SPRINT proves that lower is better for nondiabetic high-risk patients, but at a priceJournal of Immunology.  29:2-4. 2016
2015 Obstructive sleep apnea, hypertension and cardiovascular diseasesJournal of Human Hypertension.  29:705-712. 2015
2015 Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertensionKidney International.  88:622-632. 2015
2015 Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attackElectronic Journal of Biotechnology.  128:707-714.e2. 2015
2015 Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophyJournal of Human Hypertension.  29:241-246. 2015
2015 Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study.Journal of Biomedical Science and Engineering.  8:213-225. 2015
2015 Editorial comment: Change in leadershipJournal of Human Hypertension.  29:339. 2015
2015 Management of Hypertension in CKD: Beyond the GuidelinesNeuroscientist.  22:116-122. 2015
2015 Nocturnal blood pressure in young adults and cognitive function in midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) studyJournal of Immunology.  28:1240-1247. 2015
2015 Predictors of silent myocardial ischemia in resistant hypertensive patientsJournal of Immunology.  28:200-207. 2015
2015 Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the coronary artery risk development in young adults (CARDIA) studyJournal of Immunology.  28:640-648. 2015
2015 Refractory hypertension: Evidence of heightened sympathetic activity as a cause of antihypertensive treatment failureHypertension.  66:126-133. 2015
2015 Results of an academic, health care worksite weight loss contest for Southeastern Americans: Scale Back Alabama 2011-2013Workplace Health and Safety.  63:165-169. 2015
2014 Associations between vascular health indices and serum total, free and bioavailable 25-hydroxyvitamin D in adolescentsPLoS ONE.  9. 2014
2014 Left ventricular torsion shear angle volume analysis in patients with hypertension: A global approach for LV diastolic functionJournal of Cardiovascular Magnetic Resonance.  16. 2014
2014 Determination of prevalence, risk factors, and comorbidities in a large, population-based cohortHypertension.  63:451-458. 2014
2014 Management of Resistant Hypertension: Do Not Give Up on Medication.Nephrology self-assessment program : NephSAP.  13:57-63. 2014
2014 Response to comment on optimal treatment for resistant hypertension: The missing data on pulse wave velocityHypertension.  63. 2014
2014 Apparent and true resistant hypertension: Definition, prevalence and outcomesJournal of Human Hypertension.  28:463-468. 2014
2014 Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortalityJournal of the American Society of Hypertension.  8:405-413. 2014
2014 Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exerciseWorkplace Health and Safety.  62:292-300. 2014
2014 Detection, evaluation, and treatment of severe and resistant hypertension Proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, MD, USA, October 10th 2013Journal of the American Society of Hypertension.  8:743-757. 2014
2014 Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitusHypertension.  64:731-737. 2014
2014 Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: The Reasons for Geographic and Racial Differences in Stroke studyHypertension.  64:465-471. 2014
2014 Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistanceJournal of Human Hypertension.  28:416-420. 2014
2014 Incident ESRD and treatment-resistant hypertension: The reasons for geographic and racial differences in stroke (REGARDS) studyOregon Social Studies Journal.  63:781-788. 2014
2014 Pathophysiology and Treatment of Resistant Hypertension: The Role of Aldosterone and Amiloride-Sensitive Sodium ChannelsSeminars in Nephrology.  34:532-539. 2014
2014 Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension?Hypertension.  63. 2014
2014 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHATJournal of the American Society of Hypertension.  8:808-819. 2014
2014 Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Hypertension.  64:1012-1021. 2014
2013 Management of patients with resistant hypertension: Current treatment optionsIntegrated Blood Pressure Control.  6:139-151. 2013
2013 Prevalence of apparent treatment-resistant hypertension among individuals with CKDPediatric and Developmental Pathology.  8:1583-1590. 2013
2013 Increased circulating inflammatory endothelial cells in blacks with essential hypertensionHypertension.  62:585-591. 2013
2013 Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertensionJournal of Breast Cancer.  29:901-910. 2013
2013 Aldosterone receptor antagonists: Current perspectives and therapiesVascular Health and Risk Management.  9:321-331. 2013
2013 The contributions of unhealthy lifestyle factors to apparent resistant hypertension: Findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) studyJournal of Hypertension.  31:370-376. 2013
2013 Hyperaldosteronism as a common cause of resistant hypertensionJournal of Cardiovascular Electrophysiology.  64:233-247. 2013
2013 Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health systemMayo Clinic Proceedings.  88:1099-1107. 2013
2013 Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronismUrological Research.  143:978-983. 2013
2013 ResponseUrological Research.  144:720. 2013
2012 Associations of C-reactive protein to indices of vascular health and the influence of serum 25(OH)D status in healthy adultsJournal of Nutrition and Metabolism.  2012. 2012
2012 Editorial introducing David as EiCJournal of Human Hypertension.  26:517. 2012
2012 Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney diseaseJournal of Human Hypertension.  26:502-506. 2012
2012 Serum 25-hydroxyvitamin D and Ethnic Differences in Arterial Stiffness and Endothelial Function.Journal of Clinical Medicine Research.  4:197-205. 2012
2012 Response to letter to regarding article, "Effects of novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo- and active-controlled phase 2 trial"Materials Today: Proceedings.  125. 2012
2012 Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trialHypertension.  59:926-933. 2012
2012 Hypertensive crisis: Forget the numbersJournal of Hypertension.  30:882-883. 2012
2012 Resistant Hypertension and Aldosterone: An UpdateMeasurement Techniques.  28:318-325. 2012
2012 Resistant hypertension, obstructive sleep apnoea and aldosteroneJournal of Human Hypertension.  26:281-287. 2012
2012 Resistant hypertension: Incidence, prevalence, and prognosisMaterials Today: Proceedings.  125:1594-1596. 2012
2012 Relation of torsion and myocardial strains to LV ejection fraction in hypertensionJACC: Cardiovascular Imaging.  5:273-281. 2012
2012 Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whitesOregon Social Studies Journal.  59:229-237. 2012
2012 Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patientsJournal of the American Society of Hypertension.  6:66-72. 2012
2012 Hypertension and orthostatic hypotension in older patientsJournal of Hypertension.  30:38-39. 2012
2012 Prevalence and Correlates of Low Medication Adherence in Apparent Treatment-Resistant HypertensionJournal of Clinical Hypertension.  14:694-700. 2012
2012 Recent advancements in the treatment of resistant hypertensionPostgraduate Medicine.  124:67-72. 2012
2012 Refractory hypertension: Definition, prevalence, and patient characteristicsJournal of Clinical Hypertension.  14:7-12. 2012
2011 Aldosteronism and resistant hypertensionInternational Journal of Hypertension.  2011. 2011
2011 Resistant HypertensionTransactions of the Indian Institute of Metals.  5:307-313. 2011
2011 Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo- and active-controlled phase 2 trialMaterials Today: Proceedings.  124:1945-1955. 2011
2011 Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertensionJournal of Human Hypertension.  25:656-664. 2011
2011 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertensionJournal of Human Hypertension.  25:615-622. 2011
2011 Characteristics of resistant hypertension: Ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffnessJournal of Human Hypertension.  25:532-538. 2011
2011 Gene variation in resistant hypertension: Multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genesJournal of VLSI Signal Processing.  30:555-564. 2011
2011 Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse populationJournal of Hypertension.  29:1553-1559. 2011
2011 Moderate waist circumference and hypertension prevalence: The REGARDS studyJournal of Immunology.  24:482-488. 2011
2011 Apparent resistant hypertension and medication adherenceHypertension Research.  34:41-42. 2011
2011 Geographic and demographic variability in 20-year hypertension incidence: The CARDIA studyHypertension.  57:39-47. 2011
2011 Resistant hypertension: Bad and getting worseHypertension.  57:1045-1046. 2011
2010 Resistant Hypertension, Secondary Hypertension, and Hypertensive Crises: Diagnostic Evaluation and TreatmentPersonality Disorders: Theory, Research, and Treatment.  28:639-654. 2010
2010 Salt and aldosterone: A concert of bad effectsHypertension.  56:804-805. 2010
2010 Treatment of resistant hypertensionJournal of Hypertension.  28:2194-2195. 2010
2010 Response to hyperaldosteronism and left ventricular hypertrophyHypertension.  56. 2010
2010 Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertensionJournal of Clinical Sleep Medicine.  6:363-368. 2010
2010 Sleep and hypertensionUrological Research.  138:434-443. 2010
2010 Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: A preliminary reportJournal of Human Hypertension.  24:532-537. 2010
2010 The Role of Aldosteronism in Causing Obesity-Related Cardiovascular RiskPersonality Disorders: Theory, Research, and Treatment.  28:517-527. 2010
2010 Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertensionJournal of Human Hypertension.  24:483-491. 2010
2010 Obstructive sleep apnea and hypertensionConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  12:189-195. 2010
2010 Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical studyHypertension.  55:1137-1142. 2010
2010 Response to "effective" plasma renin activity: A derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockersHypertension.  55. 2010
2009 A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMRJournal of Cardiovascular Magnetic Resonance.  11. 2009
2009 Reduction of blood pressure in patients with treatment-resistant hypertensionExpert Opinion on Pharmacotherapy.  10:2959-2971. 2009
2009 Treatment of resistant hypertensionMinerva Cardioangliologica.  57:787-811. 2009
2009 Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safetyUroToday International Journal.  26:1012-1023. 2009
2009 Characterization and treatment of resistant hypertensionSolid-State and Integrated Circuit Technology.  11:407-413. 2009
2009 Current options for the treatment of resistant hypertensionExpert Review of Cardiovascular Therapy.  7:1385-1393. 2009
2009 Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trialHypertension.  54:475-481. 2009
2009 Use of single-pill combination therapy in the evolving paradigm of hypertension managementExpert Opinion on Pharmacotherapy.  10:1869-1874. 2009
2009 Resistant hypertension: Who and how to evaluateInternational Journal of Disaster Resilience in the Built Environment.  24:340-344. 2009
2009 Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: A randomized clinical trialHypertension.  54:32-39. 2009
2009 Aldosterone and metabolic dysfunction an unresolved issueHypertension.  53:585-586. 2009
2009 Sleep Apnea, Aldosterone, and Resistant HypertensionProgress in Cardiovascular Diseases.  51:371-380. 2009
2009 Efficacy and safety of initial combination therapy with amlodipine/ valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: The EX-STAND studyJournal of Human Hypertension.  23:479-489. 2009
2008 Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertensionJournal of the American Society of Hypertension.  2:462-468. 2008
2008 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: What should we remember in everyday practice?Polish Archives of Internal Medicine.  118:396-397. 2008
2008 Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertensionJournal of Breast Cancer.  24:2303-2311. 2008
2008 Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: A losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudyHypertension.  52:279-286. 2008
2008 Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansionAIS Educator Journal.  168:1159-1164. 2008
2008 Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertensionHypertension.  51:339-344. 2008
2008 Response to about an epidemic of primary aldosteronism [2]Hypertension.  51. 2008
2007 High blood pressure in older adults: A Conversation with Dr David calhounMathematics and visualization.  16:391-392. 2007
2007 Resistant hypertension and aldosteronismConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  9:353-359. 2007
2007 Aldosterone excess and resistance to 24-h blood pressure controlJournal of Hypertension.  25:2131-2137. 2007
2007 Is there an unrecognized epidemic of primary aldosteronism? (Pro)Hypertension.  50:447-458. 2007
2007 Mechanisms and treatment of resistant hypertensionMaternal-child nursing journal.  88. 2007
2007 Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension.Journal of Clinical Hypertension.  9:19-24. 2007
2007 Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertensionUrological Research.  131:453-459. 2007
2006 Aldosterone and cardiovascular disease: Smoke and fireMaterials Today: Proceedings.  114:2572-2574. 2006
2006 Aldosterone, dietary salt, and renal diseaseHypertension.  48:209-210. 2006
2006 Aldosterone antagonists: Effective add-on therapy for the treatment of resistant hypertensionExpert Review of Cardiovascular Therapy.  4:353-359. 2006
2006 Use of Aldosterone Antagonists in Resistant HypertensionProgress in Cardiovascular Diseases.  48:387-396. 2006
2006 Aldosteronism and hypertension.Pediatric and Developmental Pathology.  1:1039-1045. 2006
2006 Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countriesJournal of Hypertension.  24:435-436. 2006
2006 Primary Aldosteronism: Diagnosis and TreatmentJournal of Clinical Hypertension.  8:887-893. 2006
2006 Resistant or difficult-to-treat hypertension.Journal of Clinical Hypertension.  8:181-186. 2006
2005 HypertensionHypertension2005
2005 Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertensionJournal of Immunology.  18:805-812. 2005
2005 Aldosterone antagonism: An emerging strategy for effective blood pressure loweringConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  7:186-192. 2005
2005 Primary aldosteronism: Diagnostic and therapeutic considerationsSolid-State and Integrated Circuit Technology.  7:412-417. 2005
2005 The role of aldosterone antagonists in the management of resistant hypertensionConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  7:343-347. 2005
2004 Weight gain and hypertension: The chicken-egg question revisitedJournal of Hypertension.  22:1869-1871. 2004
2004 Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: Data from a 13-week double-blind, placebo-controlled, parallel, multicenter studyJournal of Human Hypertension.  18:655-661. 2004
2004 Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronismMaterials Today: Proceedings.  109:2857-2861. 2004
2004 Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosisGenetic Testing.  8:90-97. 2004
2004 Aldosterone Excretion among Subjects with Resistant Hypertension and Symptoms of Sleep ApneaUrological Research.  125:112-117. 2004
2004 Use of aldosterone antagonists in resistant hypertension.Journal of Clinical Hypertension.  6:458-460. 2004
2003 Pathogenesis of HypertensionThrombosis.  139:761-776. 2003
2003 Efficacy of low-dose spironolactone in subjects with resistant hypertension.Journal of Immunology.  16:925-930. 2003
2003 Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterizationJournal of Hypertension.  21:1157-1162. 2003
2003 Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization.Journal of Hypertension.  21:1157-1162. 2003
2003 Efficacy of Low-Dose Spironolactone in Subjects with Resistant HypertensionJournal of Immunology.  16:925-930. 2003
2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Journal of the American Medical Association.  288:2981-2997. 2002
2002 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)Journal of the American Medical Association.  288:2998-3007. 2002
2002 Hyperaldosteronism among black and white subjects with resistant hypertensionHypertension.  40:892-896. 2002
2002 Drugs targeting the renin-angiotensin-aldosterone systemNature Reviews Drug Discovery.  1:621-636. 2002
2002 Resistant hypertensionConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  4:221-228. 2002
2001 Hyperactive ENaC identifies hypertensive individuais amenable to amiloride therapyLife Science Alliance.  281. 2001
2001 Enalaprilat blunts reflexive increases in cardiac interstitial norepinephrine in conscious ratsJournal of Hypertension.  19:2025-2029. 2001
2001 Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy.Life Science Alliance.  281:C1413-C1421. 2001
2001 Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trialSurgical Oncology.  23:1166-1179. 2001
2000 Evaluation of low-dose endotoxin administration during pregnancy as a model of preeclampsiaIEEE Control Systems.  93:1446-1455. 2000
1999 Interaction between lifetime captopril treatment and NaCl-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto ratsJournal of Hypertension.  17:983-991. 1999
1999 Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto ratsJournal of Hypertension.  17:507-512. 1999
1999 Contemporary management of refractory hypertensionConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  1:402-407. 1999
1998 Managing the patient with hard-to-control hypertensionGeriatric Education Center.  57:1007-1014. 1998
1998 The sexual dimorphism of high blood pressureNeuroscience Research.  6:356-363. 1998
1997 High blood pressure in womenInternational Journal of Fertility and Womens Medicine.  42:198-205. 1997
1997 Fenoldopam: A novel, peripherally acting dopamine-1 agonist for parenteral treatment of hypertensionHeat and Mass Transfer.  33:729-738. 1997
1997 Race, family history of hypertension, and sympathetic response to cold pressor testingAktuality V Nefrologii.  6:209-213. 1997
1996 Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive ratsHypertension.  27:297-302. 1996
1996 Hypertension: Initial evaluationIEEE Transactions on Computers.  5:60-62. 1996
1996 Ovariectomy induces NaCl-sensitivity in female spontaneously hypertensive ratsJournal of Investigative Medicine.  44. 1996
1995 Calcium antagonists: Antihypertensive and vascular considerationsComparative Biochemistry and Physiology - A: Comparative Physiology.  16. 1995
1995 Hypertensive crisis since fdr – a partial victoryNew England Journal of Medicine.  332:1029-1030. 1995
1995 Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto ratsHypertension.  26:285-289. 1995
1995 Racial differences in the pathogenesis of hypertensionCurrent Opinion in Virology.  310. 1995
1994 Diurnal blood pressure variation and dietary salt in spontaneously hypertensive ratsHypertension.  24:1-7. 1994
1994 Muscle sympathetic nervous system activity in black and caucasian hypertensive subjectsJournal of Hypertension.  12:1291-1296. 1994
1993 Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive ratsHypertension.  22:285-291. 1993
1993 Normotensive blacks have heightened sympathetic response to cold pressor testHypertension.  22:801-805. 1993
1992 Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive ratHypertension.  20:374-379. 1992
1992 Hypertension in blacks: Socioeconomic stress and sympathetic nervous system activityCurrent Opinion in Virology.  304:306-311. 1992
1991 The calcium antagonists in the 1990s. An overview.Journal of Immunology.  4:396S-405S. 1991
1991 Treatment of hypertensive crisisNew England Journal of Medicine.  324:992-994. 1991
1991 High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive ratsHypertension.  17:363-368. 1991
1991 The calcium antagonists in the 1990s an overviewJournal of Immunology.  4:396S-405S. 1991
1990 Treatment of hypertensive crisisNew England Journal of Medicine.  323:1177-1183. 1990
1989 HypertensionJournal of Artificial Organs.  35:138-232. 1989

Chapter

Year Title Altmetric
2013 Resistant hypertension.  253-269. 2013
2013 Pathogenesis of Hypertension.  12-26. 2013
2012 Resistant hypertension.  501-509. 2012
2010 Hypertensive Emergencies.  355-367. 2010
2007 Pathophysiology of Hypertension.  25-46. 2007
2007 Resistant Hypertension.  658-665. 2007
2005 Resistant Hypertension.  616-623. 2005
2004 Hypertension and Sympathetic Nervous System Activity.  241-244. 2004

Research Overview

  • Resistant and difficult to treat hypertension
    Obstructive sleep apnea & hypertension
  • Principal Investigator On

  • Private Grant  awarded by IDORSIA PHARMACEUTICALS LTD 2018 - 2023
  • Private Grant  awarded by RECOR MEDICAL 2016 - 2023
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center - Mechanisms of Nocturnal Hypertension and Non-Dipping Blood Pressure - Project 2  awarded by American Heart Association 2015 - 2020
  • Mechanisms of Refractory Hypertension  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2020
  • Private Grant  awarded by GEORGE CLINICAL 2017 - 2018
  • Private Grant  awarded by MEDTRONIC, INC. 2012 - 2018
  • Effect of Standard vs. Intense Clinic Based Hypertension Management on Nighttime Blood Pressure (SPRINT Ancillary Study)  awarded by University of Minnesota 2013 - 2016
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • Etiology of Sleep Apnea-Related Hyperaldosteronism  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2013
  • Private Grant  awarded by FOREST RESEARCH INSTITUTE, INC. 2012 - 2013
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2009 - 2012
  • Private Grant  awarded by ELI LILLY AND COMPANY 2010 - 2011
  • Irreversible Kidney Injury in Renovascular Hypertension  awarded by MAYO CLINIC 2010 - 2011
  • Establishment of 2 Research Beds with Full Sleep-Monitoring Capabilities  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2006 - 2011
  • SCCOR in Cardiac Dysfunction and Disease - Project 2  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2005 - 2010
  • Investigator On

  • Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2024
  • Private Grant  awarded by ROX MEDICAL INC. 2018 - 2023
  • Private Grant  awarded by INSPIRE MEDICAL SYSTEMS, INC. 2017 - 2023
  • Private Grant  awarded by VASCULAR DYNAMICS INC. 2018 - 2023
  • UAB Diabetes Research Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB Diabetes Research Center - Human Physiology Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • ACES - ACE Inhibitors Combined with Exercise for Hypertensive Seniors  awarded by National Institute on Aging/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by INSPIRE MEDICAL SYSTEMS, INC. 2017 - 2022
  • Private Grant  awarded by GE HEALTHCARE 2018 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2020
  • Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease.  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2020
  • Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)  awarded by Brigham and Women's Hospital 2016 - 2020
  • Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)  awarded by Brigham and Women's Hospital 2017 - 2020
  • Private Grant  awarded by Bayer HealthCare 2015 - 2019
  • Symptoms and Skeletal Muscle in Persons with Heart Failure with Preserved Ejection Fraction  awarded by National Institute of Nursing Research/NIH/DHHS 2017 - 2019
  • Race - Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2013 - 2019
  • Cardiovascular Inflammation Reduction Trial (CIRT)  awarded by Brigham and Women's Hospital 2013 - 2019
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center  awarded by American Heart Association 2015 - 2019
  • Novel Regulators of Fibroblast Growth Factor 23 in Chronic Kidney Disease: Iron Deficiency and Hypoxia  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2017 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2018
  • Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2009 - 2018
  • Private Grant  awarded by GE HEALTHCARE 2017 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Project 2  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Racial Disparities in the Maintenance of Healthy Lifestyles and Their Effect on Cumulative Blood Pressure Burden and Left Ventricular Mass in African Americans and Whites: Data from the CARDIA Study  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2017
  • Private Grant  awarded by ASTRAZENECA AB 2013 - 2016
  • Private Grant  awarded by CVRX, INC. 2007 - 2016
  • Mitochondrial Nuclear Interactions and CVD Susceptibility  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Bayer HealthCare 2016
  • Private Grant  awarded by Bayer HealthCare 2014 - 2015
  • UAB Diabetes Research and Training Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2013
  • UAB Diabetes Research and Training Center - Human Biology Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • SCCOR in Cardiac Dysfunction and Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2005 - 2010
  • Education And Training

  • Doctor of Medicine in History, University of Virginia 1986
  • UAB Hospital, Internship 1987
  • UAB Hospital, Residency 1989
  • UAB Hospital, Postdoctoral Fellowship 1991
  • Full Name

  • David Calhoun